Dolutegravir
Thông số
1051375-16-6Số CAS
809-888-1Số EC
(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamideTên IUPAC
C20H19F2N3O5Công thức hóa học
419.4 g/molKhối lượng phân tử
Dolutegravir; 1051375-16-6; GSK1349572; S/GSK1349572; GSK 1349572; GSK-1349572; S-349572; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; DKO1W9H7M1; CHEBI:76010; DTXSID90909356; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; dolutegravirum; (4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; (4R,12aS)-N-((2,4-difluorophenyl)methyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido(5,6)pyrazino(2,6-b)(1,3)oxazine-9-carboxamide; (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide; RefChem:56964; J05AX12; DTXCID701338419; (14C)-(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-(1,3)oxazino(3,2-a)pyrido(1,2-d)pyrazine-9-carboxamide; (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid-2,4 difluorobenzylamide; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS); Tivicay; Dolutegravir (GSK1349572); (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; Dolutegravir DTG; Dolutegravir [USAN]; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide; Dolutegravir (USAN); GSK1349572A; Tivicay (TN); Dolutegravir (0.1 mg/mL in Methanol); Dolutegravir [USAN:INN]; UNII-DKO1W9H7M1; Soltegravir; Dolutegravir?; HSDB 8152; C20H19F2N3O5; MFCD20488027; S-GSK1349572; 1051375-16-6 (free); 3s3m; 3s3n; 3s3o; Dolutegravir (Standard); (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide; DOLUTEGRAVIR [MI]; DOLUTEGRAVIR [INN]; DOLUTEGRAVIR [VANDF]; SCHEMBL82071; MLS006011137; DOLUTEGRAVIR [WHO-DD]; GTPL7365; orb1300988; orb3141325; CHEMBL1229211; SCHEMBL15397915; SCHEMBL29357473; RHWKPHLQXYSBKR-BMIGLBTASA-N; GLXC-90267; EX-A1695; BDBM50062551; EBC-27030; HY-13238R; s2667; AKOS025396657; S/GSK-1349572; CCG-268876; CS-0454; DB08930; FD43372; NCGC00346629-01; NCGC00346629-02; NCGC00346629-06; NCGC00346629-11; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide; AC-28371; AS-75277; HY-13238; SMR004702915; NS00099377; T6198; S/GSK1349572,GSK1349572; D10066; EN300-7409916; F799806; Q937224; Z2235801952; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide; (4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE; (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide; (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamideTên gọi khác
Sản phẩm chứa Dolutegravir
AcriptegaDolutegravir 50mg, Lamivudine 300mg & Tenofovir Disoproxil Fumarate 300mg TabletsDolatevirDolvir TLDHetegravir 50TRIPLEVIRGSK 1349572DolutegravirdolutegravirDolutegravirDOLUTEGRAVIRDolutegravir
Trang 1/2
Công ty đang bán Dolutegravir
MP
Macleods Pharmaceuticals LimitedIndiaHD
Hangzhou Dingyan Chem Co., LtdChinaZE
Zhejiang Eazy Pharmchem Co., Ltd.ChinaCS
China Synchem Technology Co., Ltd.ChinaWH
Wuxi Hexia Chemical CompanyChinaSR
Suzhou Ryway Biotech Co., LtdChinaMP
MI Pharma Private LimitedIndiaSH
Shenzhen Haorui Pharmatech Co., Ltd.ChinaTrang 1/2